Article Sidebar
Published:
Feb 25, 2014DOI:
10.4314/tjpr.v13i2.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Ispaghula Husk-Based Extended Release Tablets of Diclofenac Sodium: Formulation, Evaluation and In vitro Release Studies
Abstract
Purpose: To formulate extended-release tablets of diclofenac sodium based on ispaghula husk
Methods: Tablets with varying proportions of diclofenac sodium and ispaghula husk were formulated by wet granulation technique at a fixed compression force of 10 kN. The formulated tablets were evaluated for physicochemical parameters as well as by Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and x-ray diffraction (XRD).
Results: Content uniformity, weight variation, thickness and friability of the formulated tablets were within acceptable limits. The hardness of the tablet decreased from 5.4 to 4.2 kg/cm2 with increasing quantity of ispaghula husk in the formulation. In contrast, disintegration time increased from 12 to 70 min with increasing amount of husk. Tablets formulated with 1:0.25 and 1:0.5 drug/husk ratio failed to extend drug release whereas tablets prepared with 1:0.75 and 1:1 ratio extended release up to 5 and 6 h, respectively. FTIR, DSC and XRD analysis of tablets revealed the absence of diclofenac–ispaghula interaction and crystalline nature of diclofenac sodium. Drug release data fitted well with Korsmeyar-Peppas and the n value of 0.98 indicate non-Fickian diffusion. The tablets were stable on storage and retained its physicochemical properties within acceptable limits.
Conclusion: The results indicate the possibility of formulating extended-release tablets based on ispaghula husk. The tablets were stable during storage and free from drug-excipient interactions. However further studies are required to ascertain the safety of the husk and to optimize the release properties of the tablets.
Keywords: Ispaghula husk, Extended release tablet, Diclofenac sodium, Release kinetics.
